AN2 Therapeutics (ANTX) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed PepGen (PEPG) over the past year, gaining 262.8% versus a loss of 51.1%. AN2 Therapeutics is the larger company by market cap ($176.6 million vs $164.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | PEPG |
|---|---|---|
| Share price | $4.68 | $2.38 |
| Market cap | $176.61M | $164.62M |
| 1-day change | -3.51% | -0.83% |
| YTD return | +310.53% | -63.44% |
| 1-year return | +262.79% | -51.13% |
| EPS (TTM) | $-1.05 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $7.80 |
| 52-week low | $1.00 | $1.31 |
| Distance from 52-week high | -34.91% | -69.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +92.31% | +328.15% |
| Average volume | 235.07K | 971.65K |
| Shares outstanding | 37.74M | 69.17M |
| Employees | 21 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed PEPG by 313.9 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ANTX vs PEPG FAQ
Which is bigger, AN2 Therapeutics or PepGen?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $176.61M compared with $164.62M for PepGen (PEPG).
Which stock has performed better over the past year, ANTX or PEPG?
ANTX returned +262.79% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.